bèta
Trial Radar AI
Eén studie komt overeen met de filtercriteria
Kaartweergave
Terug naar zoekresultaten

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial 50 Postpartum

Rekruterend
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT07449039 (POSTPOD) is een interventioneel studie bij Zwangerschapsdiabetes mellitus tijdens de zwangerschap met de status rekruterend. Het doel is om 50 deelnemers te includeren vanaf 28 september 2025. De studie wordt geleid door de Universiteit van Californië, Los Angeles en de voltooiing is gepland op 1 juni 2030. Laatste update op ClinicalTrials.gov: 4 maart 2026.
Beknopte samenvatting
This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.

Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will al...

Toon meer
Officiële titel

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

Aandoeningen
Zwangerschapsdiabetes mellitus tijdens de zwangerschap
Andere studie-ID's
  • POSTPOD
  • 25-0020
NCT-ID
NCT07449039
Startdatum (Werkelijk)
2025-09-28
Laatste update geplaatst
2026-03-04
Verwachte einddatum
2030-06
Inschrijving (Geschat)
50
Studietype
Interventioneel
FASE
N.v.t.
Status
Rekruterend
Primaire doel
Overige
Toewijzing
N.v.t.
Interventiemodel
Enkele groep
Blindering
Geen (Open-label)
Armen / Interventies
Deelnemersgroep/StudiearmInterventie/Behandeling
OverigeContinuous Glucose Monitor
Administration of a Continuous Glucose Monitor within 2 hours after delivery for 24-hour collection of glycemic data.
Continuous Glucose Monistor
Continuous glucose monitoring sensor that provides 24/7 detailed glycemic information. Participants will wear for 24 hours and then be instructed to peel off.
Primaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test
Regression analysis to assess strength and direction of the relationship between postpartum CGM data and 2 hr GTT
24 hours postpartum and 1-3 months postpartum
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum
Regression analysis to assess strength and direction of the relationship between postpartum CGM data and HbA1c
24 hours postpartum and 1-3 months postpartum
Secundaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Patient satisfaction with CGM use immediately postpartum to evaluate long term risk
Patient satisfaction will be measured via survey response on following statements using 5 point likert scale * Applying the CGM was painless. * Applying the CGM was easy. * Wearing the CGM for 24 hours postpartum was painless. * Wearing the CGM for 24 hours postpartum was easy. * Wearing the CGM did not interfere with my activities of daily living. * Wearing the CGM did not cause any side effects. * Removing the CGM was painless. * Removing the CGM was easy. * If given a choice between the 1-3 month postpartum OGTT and wearing the CGM for 24 hours immediately postpartum, I would choose wearing the CGM.
1-3 months postpartum after glucose tolerance test, 12-24 months postpartum after A1C blood test
Deelname-assistent
Geschiktheidscriteria

Leeftijd van deelnemers
Volwassene, Oudere volwassene
Minimumleeftijd
18 Years
Geslachten die in aanmerking komen voor de studie
Vrouw
  • Prenatal care at UCLA Health
  • Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
  • Confirmed gestational diabetes diagnosis based on 2-step approach
  • Maternal age >= 18 years

  • Pre-gestational diabetes (T1DM or T2DM)
  • Multifetal gestation
  • Intra-amniotic infection by clinical criteria
  • Postpartum hemorrhage
  • Maternal ICU admission
  • Known allergy to medical-grade adhesive
  • Presence of skin lesions at anticipated CGM application site
  • Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
  • Metformin use
  • Steroid use
  • Terbutaline use within 4 hours of delivery
  • Cystic fibrosis
  • MODY (mature onset of diabetes in the young)
University of California, Los Angeles logoUniversiteit van Californië, Los Angeles341 actieve klinische studies om te verkennen
Verantwoordelijke instantie
Christina S. Han, Hoofdonderzoeker, Division Director, Maternal-Fetal Medicine, University of California, Los Angeles
Centraal Contactpersoon
Contact: Rujuta Sathe, 310-794-8893, [email protected]
Contact: Dana Levin-Lopez, MPH, 310-794-8893, [email protected]
1 Studielocaties in 1 landen

California

University of California, Los Angeles, Los Angeles, California, 90095, United States
Dana Levin-Lopez, MPH, Contact, 310-794-8893, [email protected]
Rekruterend